186 related articles for article (PubMed ID: 38812672)
1. Oral Octreotide Capsules and Paltusotine in Management of Acromegaly.
McLaren DS; Seejore K; Lynch J; Murray RD
touchREV Endocrinol; 2024 Apr; 20(1):32-36. PubMed ID: 38812672
[TBL] [Abstract][Full Text] [Related]
2. ACROBAT Edge: Safety and Efficacy of Switching Injected SRLs to Oral Paltusotine in Patients With Acromegaly.
Gadelha MR; Gordon MB; Doknic M; Mezősi E; Tóth M; Randeva H; Marmon T; Jochelson T; Luo R; Monahan M; Madan A; Ferrara-Cook C; Struthers RS; Krasner A
J Clin Endocrinol Metab; 2023 Apr; 108(5):e148-e159. PubMed ID: 36353760
[TBL] [Abstract][Full Text] [Related]
3. Acromegaly Disease Control Maintained After Switching From Injected Somatostatin Receptor Ligands to Oral Paltusotine.
Gadelha MR; Casagrande A; Strasburger CJ; Bidlingmaier M; Snyder PJ; Guitelman MA; Boguszewski CL; Buchfelder M; Shimon I; Raverot G; Tóth M; Mezősi E; Doknic M; Fan X; Clemmons D; Trainer PJ; Struthers RS; Krasner A; Biller BMK
J Clin Endocrinol Metab; 2024 Jun; ():. PubMed ID: 38828555
[TBL] [Abstract][Full Text] [Related]
4. Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial.
Fleseriu M; Dreval A; Bondar I; Vagapova G; Macut D; Pokramovich YG; Molitch ME; Leonova N; Raverot G; Grineva E; Poteshkin YE; Gilgun-Sherki Y; Ludlam WH; Patou G; Haviv A; Gordon MB; Biermasz NR; Melmed S; Strasburger CJ
Lancet Diabetes Endocrinol; 2022 Feb; 10(2):102-111. PubMed ID: 34953531
[TBL] [Abstract][Full Text] [Related]
5. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide.
Samson SL; Nachtigall LB; Fleseriu M; Gordon MB; Bolanowski M; Labadzhyan A; Ur E; Molitch M; Ludlam WH; Patou G; Haviv A; Biermasz N; Giustina A; Trainer PJ; Strasburger CJ; Kennedy L; Melmed S
J Clin Endocrinol Metab; 2020 Oct; 105(10):e3785-97. PubMed ID: 32882036
[TBL] [Abstract][Full Text] [Related]
6. MPOWERED Trial Open-Label Extension: Long-term Efficacy and Safety Data for Oral Octreotide Capsules in Acromegaly.
Fleseriu M; Molitch M; Dreval A; Pokramovich Y; Bondar I; Poteshkin Y; Macut D; Obermayer-Pietsch B; Gilgun-Sherki Y; Haviv A; Biermasz N; Strasburger CJ
J Clin Endocrinol Metab; 2023 Nov; 108(12):3214-3222. PubMed ID: 37319438
[TBL] [Abstract][Full Text] [Related]
7. Oral Octreotide: A Review of Recent Clinical Trials and Practical Recommendations for Its Use in the Treatment of Patients With Acromegaly.
Yuen KCJ; Samson SL
Endocr Pract; 2022 Jun; 28(6):637-645. PubMed ID: 35452815
[TBL] [Abstract][Full Text] [Related]
8. Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers.
Madan A; Markison S; Betz SF; Krasner A; Luo R; Jochelson T; Lickliter J; Struthers RS
Pituitary; 2022 Apr; 25(2):328-339. PubMed ID: 35000098
[TBL] [Abstract][Full Text] [Related]
9. Oral octreotide capsules for acromegaly treatment: application of clinical trial insights to real-world use.
Fleseriu M; Nachtigall LB; Samson SL; Melmed S
Expert Rev Endocrinol Metab; 2024 Jul; 19(4):367-375. PubMed ID: 38842362
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial.
Melmed S; Popovic V; Bidlingmaier M; Mercado M; van der Lely AJ; Biermasz N; Bolanowski M; Coculescu M; Schopohl J; Racz K; Glaser B; Goth M; Greenman Y; Trainer P; Mezosi E; Shimon I; Giustina A; Korbonits M; Bronstein MD; Kleinberg D; Teichman S; Gliko-Kabir I; Mamluk R; Haviv A; Strasburger C
J Clin Endocrinol Metab; 2015 Apr; 100(4):1699-708. PubMed ID: 25664604
[TBL] [Abstract][Full Text] [Related]
11. Oral octreotide capsules for the treatment of acromegaly: comparison of 2 phase 3 trial results.
Labadzhyan A; Nachtigall LB; Fleseriu M; Gordon MB; Molitch M; Kennedy L; Samson SL; Greenman Y; Biermasz N; Bolanowski M; Haviv A; Ludlam W; Patou G; Strasburger CJ
Pituitary; 2021 Dec; 24(6):943-953. PubMed ID: 34173129
[TBL] [Abstract][Full Text] [Related]
12. Clinical Pharmacology of Oral Octreotide Capsules for the Treatment of Acromegaly.
Uygur MM; Villanova M; Frara S; Giustina A
touchREV Endocrinol; 2024 Apr; 20(1):37-42. PubMed ID: 38812667
[TBL] [Abstract][Full Text] [Related]
13. Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine.
Wildemberg LE; Fialho C; Gadelha MR
Best Pract Res Clin Endocrinol Metab; 2024 May; ():101906. PubMed ID: 38845246
[TBL] [Abstract][Full Text] [Related]
14. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
McKeage K; Cheer S; Wagstaff AJ
Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
[TBL] [Abstract][Full Text] [Related]
15. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
[TBL] [Abstract][Full Text] [Related]
16. Slow-release lanreotide in the treatment of acromegaly: a study in 66 patients.
Verhelst JA; Pedroncelli AM; Abs R; Montini M; Vandeweghe MV; Albani G; Maiter D; Pagani MD; Legros JJ; Gianola D; Bex M; Poppe K; Mockel J; Pagani G
Eur J Endocrinol; 2000 Nov; 143(5):577-84. PubMed ID: 11078980
[TBL] [Abstract][Full Text] [Related]
17. Paltusotine, a Novel Oral Somatostatin Receptor Ligand in the Management of Acromegaly.
McLaren DS; Murray RD
J Clin Endocrinol Metab; 2023 Apr; 108(5):e193-e194. PubMed ID: 36582134
[No Abstract] [Full Text] [Related]
18. Durable biochemical response and safety with oral octreotide capsules in acromegaly.
Samson SL; Nachtigall LB; Fleseriu M; Jensterle M; Manning PJ; Elenkova A; Molitch ME; Ludlam WH; Patou G; Haviv A; Biermasz NR; Giustina A; Strasburger CJ; Kennedy L; Melmed S
Eur J Endocrinol; 2022 Dec; 187(6):733-741. PubMed ID: 36173649
[TBL] [Abstract][Full Text] [Related]
19. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
Giustina A; Mazziotti G; Cannavò S; Castello R; Arnaldi G; Bugari G; Cozzi R; Ferone D; Formenti AM; Gatti E; Grottoli S; Maffei P; Maffezzoni F; Montini M; Terzolo M; Ghigo E
J Clin Endocrinol Metab; 2017 Jul; 102(7):2454-2464. PubMed ID: 28419317
[TBL] [Abstract][Full Text] [Related]
20. Acromegaly: Pathophysiological Considerations and Treatment Options Including the Evolving Role of Oral Somatostatin Analogs.
Daniel CP; Wagner MJ; Borne GE; Plaisance CJ; Ahmadzadeh S; Aquino A; Shekoohi S; Kaye AM; Cornett EM; Kaye AD
Pathophysiology; 2023 Sep; 30(3):377-388. PubMed ID: 37755395
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
